Literature DB >> 22517876

Risk of second cancers in chronic myeloproliferative neoplasms.

Maria Chiara Susini, Giovanna Masala, Elisabetta Antonioli, Lisa Pieri, Paola Guglielmelli, Domenico Palli, Alberto Bosi, Alessandro M Vannucchi.   

Abstract

Entities:  

Mesh:

Year:  2012        PMID: 22517876     DOI: 10.1182/blood-2011-12-401455

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

1.  A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database.

Authors:  Andrew M Brunner; Gabriela Hobbs; Marla M Jalbut; Donna S Neuberg; Amir T Fathi
Journal:  Leuk Lymphoma       Date:  2015-08-19

2.  Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Authors:  Margherita Maffioli; Toni Giorgino; Barbara Mora; Alessandra Iurlo; Elena Elli; Maria Chiara Finazzi; Marianna Caramella; Elisa Rumi; Maria Cristina Carraro; Nicola Polverelli; Mariella D'Adda; Simona Malato; Marianna Rossi; Alfredo Molteni; Alessandro Vismara; Cinzia Sissa; Francesco Spina; Michela Anghilieri; Daniele Cattaneo; Rossella Renso; Marta Bellini; Maria Luisa Pioltelli; Chiara Cavalloni; Daniela Barraco; Raffaella Accetta; Lorenza Bertù; Matteo Giovanni Della Porta; Francesco Passamonti
Journal:  Blood Adv       Date:  2019-11-12

3.  Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.

Authors:  Cristina Santoro; Isabella Sperduti; Roberto Latagliata; Erminia Baldacci; Barbara Anaclerico; Giuseppe Avvisati; Massimo Breccia; Francesco Buccisano; Michele Cedrone; Giuseppe Cimino; Cinzia De Gregoris; Marianna De Muro; Ambra Di Veroli; Sabrina Leonetti Crescenzi; Marco Montanaro; Enrico Montefusco; Raffaele Porrini; Angela Rago; Antonio Spadea; Francesca Spirito; Nicoletta Villivà; Alesssandro Andriani; Giuliana Alimena; Maria Gabriella Mazzucconi
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

4.  Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.

Authors:  Federico Lussana; Alessandra Carobbio; Silvia Salmoiraghi; Paola Guglielmelli; Alessandro Maria Vannucchi; Barbara Bottazzi; Roberto Leone; Alberto Mantovani; Tiziano Barbui; Alessandro Rambaldi
Journal:  J Hematol Oncol       Date:  2017-02-22       Impact factor: 17.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.